Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus HEPARIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus HEPARIN LOCK FLUSH.
DICUMAROL vs HEPARIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Heparin potentiates the activity of antithrombin III, inactivating thrombin and activated factor X (FXa), thereby preventing fibrin formation and thrombus propagation.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
10-100 units/mL solution, 1-2 mL flush intravascularly after each catheter use or daily when catheter is not in use; typical adult dose: 10-100 units per flush.
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
Terminal elimination half-life approximately 1-2 hours (mean 1.5 hours) at therapeutic doses; increases with dose; in renal failure, half-life prolonged up to 3-5 hours; clinical note: duration of effect short due to rapid clearance, requiring continuous infusion or frequent dosing.
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Primarily renal via glomerular filtration and tubular secretion; about 50% excreted unchanged in urine; remainder metabolized in the liver and reticuloendothelial system (heparinase); fecal elimination negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant